Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients.
Tanner M JohnsonAmanda H HowardMatthew A MillerLorna L AllenMisha HuangKyle C MolinaValida BajrovicPublished in: Open forum infectious diseases (2021)
In a cohort of primarily SOT recipients, bezlotoxumab was well tolerated and associated with lower odds of recurrent CDI at 90 days. Larger, prospective trials are needed to confirm these findings among SOT and HCT populations.